Machine learning risk prediction model for acute coronary syndrome and death from use of non-steroidal anti-inflammatory drugs in administrative data.
Acute Coronary Syndrome
/ drug therapy
Anti-Inflammatory Agents, Non-Steroidal
/ therapeutic use
Area Under Curve
Australia
/ epidemiology
Cause of Death
Comorbidity
Disease Management
Disease Susceptibility
Female
Humans
Machine Learning
Male
Models, Theoretical
Prognosis
Proportional Hazards Models
ROC Curve
Risk Assessment
/ methods
Risk Factors
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
15 09 2021
15 09 2021
Historique:
received:
22
01
2021
accepted:
20
08
2021
entrez:
16
9
2021
pubmed:
17
9
2021
medline:
15
12
2021
Statut:
epublish
Résumé
Our aim was to investigate the usefulness of machine learning approaches on linked administrative health data at the population level in predicting older patients' one-year risk of acute coronary syndrome and death following the use of non-steroidal anti-inflammatory drugs (NSAIDs). Patients from a Western Australian cardiovascular population who were supplied with NSAIDs between 1 Jan 2003 and 31 Dec 2004 were identified from Pharmaceutical Benefits Scheme data. Comorbidities from linked hospital admissions data and medication history were inputs. Admissions for acute coronary syndrome or death within one year from the first supply date were outputs. Machine learning classification methods were used to build models to predict ACS and death. Model performance was measured by the area under the receiver operating characteristic curve (AUC-ROC), sensitivity and specificity. There were 68,889 patients in the NSAIDs cohort with mean age 76 years and 54% were female. 1882 patients were admitted for acute coronary syndrome and 5405 patients died within one year after their first supply of NSAIDs. The multi-layer neural network, gradient boosting machine and support vector machine were applied to build various classification models. The gradient boosting machine achieved the best performance with an average AUC-ROC of 0.72 predicting ACS and 0.84 predicting death. Machine learning models applied to linked administrative data can potentially improve adverse outcome risk prediction. Further investigation of additional data and approaches are required to improve the performance for adverse outcome risk prediction.
Identifiants
pubmed: 34526544
doi: 10.1038/s41598-021-97643-3
pii: 10.1038/s41598-021-97643-3
pmc: PMC8443580
doi:
Substances chimiques
Anti-Inflammatory Agents, Non-Steroidal
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
18314Informations de copyright
© 2021. The Author(s).
Références
Gastroenterol Hepatol Bed Bench. 2012 Spring;5(2):79-83
pubmed: 24834204
Sci Rep. 2020 Jun 9;10(1):9289
pubmed: 32518246
J Epidemiol Community Health. 2011 Apr;65(4):315-9
pubmed: 20427550
Spine J. 2019 Nov;19(11):1772-1781
pubmed: 31229662
Aust N Z J Public Health. 1999 Oct;23(5):453-9
pubmed: 10575763
PLoS One. 2009;4(2):e4439
pubmed: 19209224
Arch Intern Med. 2009 Jan 26;169(2):141-9
pubmed: 19171810
IEEE J Biomed Health Inform. 2018 Sep;22(5):1589-1604
pubmed: 29989977
Drug Saf. 2019 Jun;42(6):721-725
pubmed: 30725336
J Pediatr. 2008 Mar;152(3):416-21
pubmed: 18280852
JAMA. 2016 Feb 9;315(6):551-2
pubmed: 26864406
J Pain Res. 2015 Feb 20;8:105-18
pubmed: 25759598
Heart Lung Circ. 2010 Dec;19(12):717-25
pubmed: 20864399
JAMA Netw Open. 2019 Mar 1;2(3):e190968
pubmed: 30901048
Ther Adv Drug Saf. 2016 Feb;7(1):11-22
pubmed: 26834959
Int J Environ Res Public Health. 2020 Jan 23;17(3):
pubmed: 31979257
PLoS Med. 2011 Sep;8(9):e1001098
pubmed: 21980265
J Am Heart Assoc. 2017 Dec 20;6(12):
pubmed: 29263033
Rheumatology (Oxford). 2015 Apr;54(4):736-42
pubmed: 25252703
Expert Rev Clin Pharmacol. 2016 Nov;9(11):1479-1492
pubmed: 27575590
Nat Rev Cardiol. 2011 Jan;8(1):30-41
pubmed: 21060326
Heart. 2006 Nov;92(11):1610-5
pubmed: 16717069
Annu Int Conf IEEE Eng Med Biol Soc. 2017 Jul;2017:3110-3113
pubmed: 29060556
BMJ. 2017 May 9;357:j1909
pubmed: 28487435
J Biomed Inform. 2021 Jan;113:103627
pubmed: 33259944
Clin Interv Aging. 2016 May 02;11:497-505
pubmed: 27194906
JAMA. 2016 Feb 16;315(7):651-2
pubmed: 26881365
Nat Rev Cardiol. 2020 Sep;17(9):574-584
pubmed: 32322101
Int J Environ Res Public Health. 2020 Jan 31;17(3):
pubmed: 32023993
Public Health Res Pract. 2015 Sep 30;25(4):e2541546
pubmed: 26536508
Comput Methods Programs Biomed. 2018 Nov;166:123-135
pubmed: 30415712
Br J Clin Pharmacol. 2004 Jan;57(1):6-14
pubmed: 14678335
Biom J. 2005 Aug;47(4):458-72
pubmed: 16161804
Heart. 2018 Dec;104(23):1937-1948
pubmed: 29921571
JAMA Netw Open. 2020 Jan 3;3(1):e1918962
pubmed: 31922560
BMJ Open. 2014 Sep 18;4(9):e006258
pubmed: 25234510
N Engl J Med. 2005 Mar 17;352(11):1092-102
pubmed: 15713943
BMJ. 2016 Sep 28;354:i4857
pubmed: 27682515